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SUMMARY
What is known and Objective: Despite the avail-
ability of effective treatments for the manage-
ment of corticosteroid-induced osteoporosis
(CIOP), the condition is undertreated. Our
objective was to assess prescribers’ knowledge
and likely prescribing patterns concerning the
diagnosis and treatment of CIOP. Another goal
was to identify key barriers to the use of pre-
ventive therapy in patients using long-term cor-
ticosteroids.
Methods: We used a postal survey of general
practitioners (GPs) and specialists in the Nether-
lands. The survey comprised of questions on:
demographic data, perceived barriers to the use of
preventive therapy for CIOP, and knowledge of
diagnosis and treatment of CIOP. Case scenarios
were questioned to assess practice patterns.
Results: Responding prescribers correctly
answered an average of 55% of knowledge
questions and 69% of case scenarios. Multiple
questions and cases showed that knowledge on
the use of bone mineral density (BMD) determi-
nation was poor. BMD was determined in
patients who, according to the national osteopo-
rosis guideline, should be treated with bis-
phosphonates independent of BMD. Moreover,
only 18% of doctors correctly answered that the
BMD cutoff in CIOP patients is a T-score of £)1
or £)1Æ5. Key barriers identified were: (i) GPs,
significantly more than specialists, consider pre-
scription of preventive therapy the responsibility
of another doctor; (ii) discontinuation of anti-
resorptive medication due to adverse effects and
(iii) the reluctance to prescribe preventive therapy
in patients already prescribed multiple medica-
tions.
What is new and Conclusion: Doctors did not
identify many barriers to the prescribing of anti-
resorptive therapies. Lack of knowledge, espe-
cially concerning use of BMD-results, likely led
to the under-treatment of the presented patients.
Keywords: bone mineral density, corticosteroid,
knowledge, osteoporosis, prevention, survey
WHAT IS KNOWN AND OBJECTIVE
Osteoporosis is a major concern for both the indi-
vidual patient and to the general community due to
increased morbidity, mortality (1,2), and financial
costs arising from fractures (3). It has been shown
that fractures can profoundly threaten the quality
of life of the elderly, and the consequences of
ignoring osteoporosis until fractures occur often
are dramatic for elderly patients (3–5). Further-
more, the number of fractures is expected to
increase in the community due to the world’s
ageing population (6).
A number of studies have reported decreases in
BMD and ⁄ or an increase in fracture risk during
oral corticosteroid treatment (7–9). Corticosteroid-
induced osteoporosis (CIOP) is the most common
type of secondary osteoporosis (10).
Despite the availability of effective treatments
(11), CIOP is under-treated, even in high risk
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groups of individuals who have suffered previous
fractures (12). A recent systematic review of
24 studies between 1995 and 2006 showed that the
average pharmacological prophylaxis rate was
31 ± 25% (range 1–86) for bisphosphonates,
41 ± 23% (range 7–86) for any antiresorptive
treatment (excluding calcium and vitamin D) and
54 ± 30% (range 11–93) for any treatment
(including calcium and vitamin D) (13). More
recent intervention studies showed treatment
rates for any osteoporosis prophylaxis (excluding
calcium and vitamin D) of only 35% (14), 47Æ5%
(15), 54% (16) and 57% (17) of patients at risk of
CIOP.
The under-recognition and under-treatment of
osteoporosis in general has been demonstrated in
surveys to be related to physician, patient and
healthcare system barriers (18). A previous study
by Taylor et al. (19) demonstrated that surgeons
regard primary care physicians responsible for any
investigation and subsequent medical treatment of
fracture. In addition, primary care physicians seem
not convinced of the efficacy over the adverse
outcomes and associated costs (20) and require
more information regarding BMD testing (21).
Patient factors have also been investigated, with
perception and beliefs about treatment also con-
tributing to the under-treatment or unwillingness
to accept treatment (22).
In the Netherlands, due to its geography and
healthcare system, most patients have access to
BMD testing and to effective, affordable therapy.
The Dutch osteoporosis guidelines recommend
initiation of preventive therapy independent of
BMD in patients using more than 15 mg ⁄day
prednisolone, in post-menopausal women or men
>70 years using more than 7Æ5 mg ⁄day predniso-
lone (23–25) (see Fig. 1).
There is evidence demonstrating the usefulness
of academic detailing to increase prescription rates
for patients prescribed corticosteroids (12).
Although not directly investigated, a lack of pre-
ventive therapy in patients prescribed corticoster-
oids maybe due to doctors not being aware that
corticosteroids increase risk of fracture, indepen-
dently of BMD (26), and that patients receiving
long-term oral corticosteroids should be considered
for preventive therapy. The study of Werner and
Vered (27) showed adequate knowledge on diag-
nosis and management of osteoporosis. However,
only one question on CIOP was incorporated in the
survey. The study of Buckley et al. showed that
doctors’ judgment of the risk of CIOP varied sig-
nificantly by physician specialty (28). A Danish
study by Nielsen et al. (29) showed that knowledge
of the use of BMD, BMD cutt-off values, and
corticosteroid dose and length of use in relation to
prevention of CIOP is insufficient. Finally, a study
by Guzman-Clark et al. (30) determined that barri-
ers in CIOP management were lack of knowledge,
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Fig. 1. Overview of Dutch CIOP
guidelines (23–25). *Cut-off T-score
<)1 or <)1.5 (24).
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There have been no specific studies conducted
regarding doctors’ knowledge on CIOP in relation
to treatment of (hypothetical) patients and barriers
to the prevention of CIOP. Our objective was to
determine the knowledge and likely prescribing
practices of GPs and medical specialists concerning
the diagnosis and treatment of CIOP. A second aim
of this research was to assess general practitioners
(GPs) and medical specialists perceptions of barri-
ers to the use of preventive therapy (including
patient barriers) in patients undergoing long-term
corticosteroid use.
METHODS
A postal survey was undertaken among registered
GPs and physicians from different specialties
(rheumatologists, general physicians, orthopedic
surgeons, respiratory physicians, gynecologists,
neurologists, geriatricians and dermatologists) in
the Netherlands. A pilot study was conducted in
2004 (31) and the final survey was administered in
2007. Respondents were included only once.
Doctors were sent a personalized letter of
explanation and a survey. Replies were returned
via an enclosed postage-paid envelope. A follow-
up reminder letter was sent to all non-responding
doctors approximately 1 month after the initial
letter was sent. A brief preliminary section of the
survey form dealt with the demographics of the
doctor (years as doctor, age, sex, practice popula-
tion (young, old, mix of young and old) and the use
of Dutch CIOP guidelines (seldom or never,
sometimes, always or regularly). Doctors were also
asked whether they thought that CIOP was an
important clinical problem.
The first section of the survey sought doctors’
opinions on barriers to the use of anti-resorptive
drugs. This section sought responses from state-
ments on a 100 mm Visual Analogue Scale (VAS),
with extremes marked ‘agree completely’ and
‘disagree completely’ and the possibility to mark ‘I
don’t know’.
The second section of the survey consisted of
questions to assess prescribers’ knowledge of
diagnosis and treatment of CIOP. In the 2004 sur-
vey, knowledge questions were answered using a
100 mm VAS, with extremes marked ‘agree com-
pletely’ and ‘disagree completely’ and the possi-
bility to mark ‘I don’t know’. The knowledge
questions in the 2007 survey were multiple choice,
using simple statements like: ‘True’, ‘False’, ‘I don’t
know’ (see Table 3). The correct answers to the
questions were determined using the existing
Dutch guidelines (23–25).
There were 11 case scenarios using hypothetical
patients prescribed corticosteroids given in the
third section of the survey, in which doctors had to
indicate what intervention they felt was appropri-
ate (e.g., bisphosphonate, calcium and vitamin D,
BMD-determination, etc.) (see Table 4). Strontium-
ranelate became one of the treatment options only
in the 2007 survey since it was not yet registered in
2004 in the Netherlands.
Statistics
The survey responses were treated anonymously,
and data from all the responses were pooled. Upon
receipt of the completed survey forms, the data were
entered, stored and analysed. All analyses were
performed using SPSS version 15 (SPSS, Chicago, IL
USA). The VAS scores were transferred into scores
using a five-point Likert-scale, selecting the nearest
integer number on the scale. For the answers on the
knowledge questions in the 2004 survey, the four
outer scores, i.e. ‘(dis)agree completely’ and ‘(dis)-
agree’, were transferred into Yes and No (depend-
ing on the question). A middle score was marked as
‘I don’t know’. Respondents that answered less than
the arbitrary cut-off point of <15% of the questions
of a specific part of the survey were excluded from
the analysis of that part of the survey.
Differences between normally distributed data
(e.g. years as doctor or age and type of doctor) were
tested using an independent Student’s t-test.
Relationships between data that were not normally
distributed (e.g., variables such as type of doctor and
perceptions of barriers to the use of anti-osteoporosis
therapy) were investigated using non-parametric
statistical procedures (Mann–Whitney U test). To
compare the relationships between type of doctor
and categorical responses, chi-square tests or
Fisher-exact tests were used. A P-value <0Æ05 was
considered statistically significant.
RESULTS AND DISCUSSION
Of the 390 survey forms mailed to doctors, 114
were returned, yielding a 29% response rate. The
 2010 Blackwell Publishing Ltd, Journal of Clinical Pharmacy and Therapeutics, 36, 356–366
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demographics of doctors are shown in Table 1.
Ninety-two percent of responding doctors indi-
cated that CIOP was an important clinical problem.
However, only 66% of responding doctors always
or regularly used Dutch CIOP management
guidelines. There were no significant differences
between GP’s and specialists.
There were few barriers identified to the pre-
scribing of anti-resorptive therapy by doctors
(Table 2). The primary concerns were: (i) GPs,
significantly more than specialists, consider pre-
scription of preventive therapy the responsibility of
another doctor; (ii) discontinuation of anti-resorp-
tive medication due to adverse effects and (iii) the
reluctance to prescribe preventive therapy in those
patients already prescribed multiple medications.
GPs had significantly higher mean VAS scores
when compared with specialists. Significantly more
GPs felt their knowledge of the current guidelines
was insufficient. This section of the survey also
showed that 28% of doctors did not know whether
patients intolerant of a bisphosphonate can be
treated with another bisphosphonate (32).
The responses from doctors concerning their
knowledge are shown in Table 3-A. The mean
percentage of correctly answered questions per
respondent was 55%. Sixteen percent of all doctors
correctly answered ‡70% of the questions. Signifi-
cant differences were shown between GPs and
specialists in Table 3-B. There was no significant
difference in the mean percentage correctly
answered questions between the two groups.
More than 40% of respondents did not know
that strontium ranelate and raloxifene were not
approved for the prophylaxis of CIOP and whether
or not the use of bisphosphonates is restricted in
patients with impaired liver- or kidney function. It
is remarkable that only 18% of doctors knew the
correct BMD T-score cut-off for CIOP (£)1 or
£)1Æ5). This is confirmed by the fact that 36% of
respondents disagreed with the statement that the
diagnosis of CIOP can only be made if the BMD
T-score is £)2Æ5.
Decisions to treat and the type of treatment
chosen by respondents for various hypothetical
patients prescribed corticosteroids (case scenarios)
are shown in Table 4. It is apparent that the per-
centage of correctly answered cases increases when
a BMD-measurement was performed and the
patient had suffered a fracture. A patient with a
T-score of )2Æ6 was most likely to receive adequate
treatment. In the majority of cases the most
frequent incorrect decision was an unnecessary
BMD-determination. On average respondents
treated 69% of patients according to the current
guideline. Sixty-five percent of all doctors correctly
answered ‡70% of the cases. There were no sig-
nificant differences between GPs and specialists
(data not shown).
Summary of main findings
The intention of this survey was to investigate the
reasons for the discrepancy between guideline
Table 1. Demographics from responding doctors
All doctors (n = 114) GPs (n = 88) Specialists (n = 26) P value
Mean age (years, range) 48 (35–60) 48 (35–58) 47 (36–60) 0.50
Sex: males (%) 68 69 64 0.67
Mean years registered (range) 18 (4–35) 18 (4–35) 18 (6–34) 0.89
Patient demographics (%)
Young 7 8 4 0.13
Old 15 13 23
Mix of young and old 78 80 73
Use of Dutch CIOP management guidelines (%)
Always or regularly 66 63 73 0.70
Sometimes 20 22 12
Seldom or never 15 15 15
CIOP is an important clinical problem; Yes (%) 92 89 100 0.48
CIOP, corticosteroid-induced osteoporosis; GPs, general practitioner.
 2010 Blackwell Publishing Ltd, Journal of Clinical Pharmacy and Therapeutics, 36, 356–366
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recommendations for CIOP and clinical practice.
The study showed that 69% of hypothetical
patients were treated according to the guidelines.
However, on average, 55% of knowledge questions
were answered correctly, with only 16% of doctors
answering more than 70% of questions correct.
Knowledge on BMD-determination and (relative)
contraindications for bisphosphonate treatment
were the main problem areas. The lack of knowl-
edge of BMD-determination was confirmed by the
hypothetical cases, as the largest percentage of
doctors answered incorrectly that a BMD-mea-
surement was necessary.
This study has identified several barriers per-
ceived by GPs in the treatment and prevention of
CIOP. Remarkably, specialists overall did not
identify any barriers. Most striking was the
perception by GPs that commencement of pre-
ventive therapy was the responsibility of special-
ists, while GPs often manage repeat prescriptions
of corticosteroids. Other barriers were polyphar-
macy and discontinuation of medication by
Table 2. Perceived barriers to the treatment of CIOP by doctors
Barrier








1. It’s often the responsibility of
another doctor (e.g. specialist or
general practitioner, vice versa)
2.6 ± 1.4 (3) 2 2.9 ± 1.4 (3) 1.5 ± 1.0 (1) 0.002
2. Many patients cease therapy for
osteoporosis prevention ⁄ treatment
due to adverse effects
2.6 ± 1.3 (3) 2 2.7 ± 1.3 (3) 2.3 ± 1.5 (2) 0.17
3. Difficulty prescribing more
medications to patients on multiple
medications
2.3 ± 1.4 (2) 0 2.4 ± 1.4 (3) 1.8 ± 1.3 (1) 0.06
4. Patients are concerned about
adverse effects from
anti-osteoporosis medications
2.3 ± 1.3 (2) 7 2.3 ± 1.3 (2) 2.1 ± 1.4 (2.5) 0.72
5. Bisphosphonates have a difficult
intake advice causing
non-adherence
2.0 ± 1.2 (2) 2 2.0 ± 1.1 (2) 1.9 ± 1.5 (1) 0.41
6. A lack of interest by the patient
for osteoporosis prevention
1.8 ± 1.2 (2) 2 2.0 ± 1.2 (2) 1.4 ± 1.2 (1) 0.06
7. There is a lack of time to discuss
CIOP with the patient
1.8 ± 1.3 (1) 1 1.8 ± 1.2 (1) 1.8 ± 1.4 (1) 0.84
8. My knowledge of the current
CIOP guidelines is insufficient
1.7 ± 1.5 (1) 0 2.1 ± 1.5 (2) 0.5 ± 0.5 (0) 0.001
9. Patients intolerant of one
bisphosphonate should not
receive another bisphosphonate
1.7 ± 1.3 (1) 28 1.9 ± 1.3 (1) 0.9 ± 1.0 (1) 0.002
10. The safety of the available
medications could be better
1.7 ± 1.2 (1) 20 2.0 ± 1.2 (1.5) 1.0 ± 1.2 (1) 0.03
11. There are often contraindications
to therapy
1.7 ± 1.1 (1) 3 1.8 ± 1.0 (2) 1.4 ± 1.3 (1) 0.03
12. The existing guidelines are
difficult to translate into practice
1.7 ± 1.1 (1) 7 1.9 ± 1.1 (2) 1.1 ± 1.0 (1) 0.008
Mean ± SD per respondent (95% CI) 1.9 ± 0.7 – 2.0 ± 0.6 (1.8–2.1) 1.4 ± 0.8 (1.1–1.7) 0.003
Statements were translated from Dutch.
SD, standard deviation; CIOP, corticosteroid-induced osteoporosis; GPs, general practitioners. 1 = disagree completely; 2 = disagree;
3 = no opinion; 4 = agree; 5 = agree completely.
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Table 3. (A) Doctors knowledge concerning CIOP risk factors and treatment. (B) Differences in knowledge of GPs and
Specialists concerning CIOP
Statement









1. Strontium ranelate can be prescribed for the
prevention of CIOP
No 10 49 41
2. What is the BMD cut-off value for treatment
of CIOP (T-score: <)0.5, <)1, <)1.5, <)2,
<)2.5)
<)1, <)1.5 18 46 36
3. Raloxifene can be prescribed for the
prevention of CIOP
No 28 21 51
4. Supplementation of vitamin D in patients
treated with bisphosphonates is necessary





5. The diagnosis of CIOP can only be made if the
BMD T-score is £)2.5
No 36 23 41
6. A patient with a GFR <30mL ⁄min should not
receive a bisphosphonate
Yes 46 13 41
7. A patient with a history of reflux, dyspepsia
or GI-bleeding should NOT be prescribed a
bisphosphonate
No 47 40 13
8. A patient with impaired liver function should
NOT receive a bisphosphonate
No 50 4 47
9. BMD measurements can be used to determine
therapy adherence
No 57 31 12
10. The deleterious effects on the bone from
corticosteroids is NOT reversible
No 59 22 19
11. Inhaled corticosteroids increase the risk of
bone loss and fracture
No 64 26 11
12. Corticosteroids increase the risk of fracture
in the first 6–12 months
Yes 66 11 23
13. Corticosteroids increase the risk of fracture
independently of BMD
Yes 74 12 14
14. Calcium supplements should usually be






15. A patient treated with a NSAID should NOT
receive bisphosphonate therapy
No 82 5 14
16. Bisphosphonates are first line therapy for
prevention of CIOP
Yes 86 5 9
17. Corticosteroids increase the risk of fracture
ONLY if the dose is ‡15 mg ⁄day
No 89 2 9
18. Patients with normal BMD and a high dose
(‡15 mg ⁄day) corticosteroid should NOT
receive preventive therapy for osteoporosis
No 91 5 5
Mean percentage correct per respondent (SD) 55 (±17)
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patients. Therefore, this study highlights that not
only prescriber barriers but also patients barriers
concerning adherence contribute to the low pre-
vention rates of CIOP.
Strengths and limitations of the study
There are some limitations to our survey. The study
size was limited, which limits generalization and
statistical comparison between doctors. Respon-
dents may be those with greater interest and
knowledge in the area. As we did not obtain non-
responder data, we cannot comment on responder
bias. The response rate was 29%, similar to that
achieved in other surveys of doctors treatment
practices (33) and was considered acceptable con-
sidering the length of the questionnaire (8 pages)
(34). For example an osteoporosis knowledge sur-
vey of Werner and Vered (27) showed a response
rate of only 19%. Some respondents may have used
references to answer the questions. This would, if
they had not, have given a poorer picture of the
respondents’ knowledge. Finally, the questions
concerning the use of raloxifene and strontiumra-
nelate for CIOP could have been misinterpreted.
Possibly doctors did not know whether the ques-
tion meant: is licensed, is recommended in the
guideline, or is evidence based. This might explain
the fact that, respectively, 51% and 41% of
respondents marked ‘I don’t know’.
The hypothetical educational cases, while having
several limitations, offer a novel approach to
identify doctors’ behaviour with regards to treat-
ment decisions and some of the possible reasons
for under-treatment of CIOP. Another strength of
our study was that determination of the correct
answers for knowledge questions was based upon
the prevalent Dutch guidelines and therefore
represents testing of knowledge a corticosteroid
prescriber is expected to have (23–25).
Comparison with existing literature
This study showed that 92% of responding doctors
consider osteoporosis an important side effect of
corticosteroids. In the study of Buckley in 1998,
<50% of physicians surveyed listed osteoporosis as
one of the three most significant side effects (28).
This difference might represent an improvement of
interest in osteoporosis, but could also be caused
by methodological differences between the studies
or differences between the investigated countries.
Polypharmacy was one of the more pronounced
barriers in this survey. Doctors are often dealing
with patients with complex medical problems
requiring multiple medications and may not
always consider osteoporosis prevention in corti-
costeroid users (35).
This survey identified that many doctors were




Correct answer GP Specialist P value
(B)
1. Strontium ranelate can be prescribed for
the prevention of CIOP
No 4 33 0.01
2. 11. Inhaled corticosteroids increase the risk
of bone loss and fracture
No 77 14 <0.001
3. 18. Patients with normal BMD and a high
dose (‡ 15mg ⁄day) corticosteroid should
NOT receive preventive therapy for
osteoporosis
No 97 70 0.03
Mean percentage correct per respondent
(SD)
55 (±16) 55 (±23) 0.95
Statements were translated from Dutch to English.
SD, standard deviation; CIOP, corticosteroid-induced osteoporosis; BMD, bone mineral density; GP, general practitioner.
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bisphosphonate can be treated with another bis-
phosphonate. Available data show that previously
intolerant patients often accept bisphosphonate
therapy upon re-challenge (36). In the Netherlands,
data show that approximately 20% of patients
cease taking alendronate after the dispensing of the
first prescription (37). This might be due to adverse
events or inadequate patient education.
Specialists and GPs displayed similar levels of
knowledge relating to CIOP with scope for
improvement. Similar to previous surveys (19, 30),
GPs indicated (voluntarily) that more education is
required to increase awareness and knowledge of
CIOP. The use of inhaled corticosteroids and risk of
fracture showed the greatest difference between
GPs and specialists in our survey. The issue of
whether inhaled corticosteroids increases the risk
of fractures independently of the underlying con-
dition they are treating (COPD ⁄ asthma) is vexing.
Current evidence shows that when fracture risk is
Table 4. (A) Percentage correct answers for case scenarios of long-term users (10mg ⁄day prednisolone). (B) Treatment
decisions for case scenarios of long-term prednisolone users (10 mg ⁄day prednisolonea)
Case
Type of case scenario
Correct (%)
(n = 103)Sex Age T-score Fracture Other
(A)
1 F 65 – – 5 mg ⁄day 42
2 F 45 )1.8 – 53
3 F 80 – – 58
4 F 80 – Vert Early dementia 67
5 F 65 – Wrist 72
6 F 65 )1.8 – 74
7 M 70 )1.8 – 74
8 M 70 )1.7 Wrist 79
9 F 65 )1.8 Wrist 81
10 F 80 – Vert 82




1st Choice treatment (%)
Case scenario (n = 103)
1a 2 3 4 5 6 7 8 9 10 11
(B)
Bisphosphonate (and calcium + vitamin Dc) 22 53b 54b 62b 56b 74b 74b 79b 81b 72b 84b
Repeat BMD 1 year – 23 – – – 12 13 7 2 – 1
Determine BMD and possibly treat 42b – 26 4 24 – – – – 7 –
Determine BMD and treat with
bisphosphonate
2 – 4b 5b 16b – – – – 10b –
Calcium + vitamin D 6 8 7 10 0 6 5 7 9 2 3
Raloxifene (and calcium + vitamin Dc) 2 12 2 5 3 1 2 4 5 4 8
Strontiumranelate (and vitamin Dc) 0 0 0 2 0 3 0 0 0 1 0
Do nothing 16 2 4 7 0 4 3 1 0 2 1
Other 6 3 2 4 0 1 0 1 4 2 1
Don’t know 5 0 1 2 1 0 3 2 0 1 3
T-score, outcome of bone mineral density determination; Vert, vertebral; M, male; F, female.
aPatient in case scenario 1 uses 5 mg ⁄day.
bCorrect answer.
cDepending on diet and sun exposure.
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adjusted for severity of disease, even high dose
inhaled corticosteroids show no increased risk (38,
39). The difference between GPs and specialists
might be explained by the fact that specialists see
more patients using high dose inhaled corticoster-
oids and therefore see more CIOP, as, in real
practice, they do not adjust for disease severity.
However, because of the low number of respond-
ing specialists, this cannot be confirmed.
Of particular importance, 34% of respondents
did not know that the risk of the onset of CIOP was
greatest in the first 3–12 months of therapy. In the
study by Nielsen et al., (29) only 23% of prescribers
would start anti-osteoporotic treatment within
6-months of corticosteroid use. Moreover, only
18% of doctors correctly knew that the BMD cut-off
values for treatment of CIOP are £)1 or £)1Æ5. The
prevalent regional GP and Dutch rheumatologist
consensus guideline on corticosteroid induced
osteoporosis mentions £)1 or £)1Æ5 (24) as the cut-
off values. The low percentage of correct answers
might also be explained by the fact that the Dutch
GP osteoporosis guideline (23) mentions no sepa-
rate BMD cut-off value for CIOP. This guideline
uses a T-score cut-off of £)2Æ5 for treating post-
menopausal osteoporosis. The Dutch CBO osteo-
porosis guideline (25) did mention a T-score cut-off
of £)2Æ5 for CIOP, with a note that the fracture
threshold might be 1 SD higher. However, in the
study by Nielsen et al., only 25% of respondents
chose a BMD <1Æ0 as a treatment threshold (29),
which is comparable with our results.
Examining the responses from the case scenar-
ios, doctors were generally less likely to prescribe a
bisphosphonate unless a BMD had been per-
formed. Approximately, 21% of all doctors chose
not to do anything for a 65-year-old women treated
with 5 mg prednisolone (case 1), despite guidelines
recommending BMD testing in women >65 years
regardless of other risk factors (24, 40). This may be
because, in the doctor’s experience, patients may be
unwilling to commence therapy unless a BMD is
performed (41, 42). However, even in patients with
a BMD T-score of )1Æ5 or lower, doctors were still
hesitant to prescribe a bisphosphonate, unaware
that the interventional T-score threshold to treat
corticosteroid users is lower than for senile osteo-
porosis, as shown in the knowledge section.
Only 53% of doctors would start preventive
treatment in a 45-year-old female using 10 mg ⁄day
with a BMD T-score of )1Æ8. A previous sur-
vey had already shown that for a 65-year-old
post-menopausal woman using prednisolone
(40 mg ⁄day tapering to 20 mg ⁄day), 80% of doc-
tors would prescribe CIOP prophylaxis, while this
was only 25 and 10% in a 45-year-old premeno-
pausal female and a 45-year-old male respectively
(28). The conclusion is that doctors seem to
underestimate the risk of CIOP in younger
patients.
WHAT IS NEW AND CONCLUSION
This survey disclosed only a few important barriers
and reasons why some patients are undertreated,
including the responsibility of GPs for repeat pre-
scriptions of corticosteroids, polypharmacy and
especially doctors’ knowledge of BMD-determina-
tion. Lack of knowledge, especially concerning use
of BMD-results, likely led to the under-treatment of
the presented patients. There is a need for a larger
study to be undertaken among doctors, as well as
investigations into specific patient barriers in the
use of osteoporosis prevention by corticosteroid
users. Future studies should focus on interventions
in patients selected based on risk in order to start
preventive therapy. The effect of pharmacists or
specialized nurses assisting prescribers on case-
finding, therapy selection and non-adherence
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